Announcement • Mar 28
CHOSA Oncology AB Presents Positive Data on Platin-DRP Predicting Overall Survival in Advanced NSCLC CHOSA Oncology AB announced presentation of positive data from its collaboration with international lung cancer experts in the European Thoracic Oncology Platform (ETOP IBCSG Partners Foundation) and the European Organisation for Research and Treatment of Cancer (EORTC). The project evaluates CHOSA's Platin-DRP in patients with advanced non-small cell lung cancer (NSCLC) treated with platinum-based chemotherapy in the Phase III SPLENDOUR trial. The translational analysis included 82 patients, of whom 28 were treated with cisplatin and 54 with carboplatin. The data presented at ELCC showed that, in the pooled cohort, higher Platin-DRP scores were associated with statistically significant improvement in both progression-free survival (PFS) and overall survival (OS). Overall survival showed the strongest association, with a hazard ratio of 0.602 (p = 0.011) for 50-point increase of DRP score. For progression-free survival, the hazard ratio was 0.697 (p = 0.029). Using the predefined 50% threshold in the pooled cohort, patients with high Platin-DRP scores had a median overall survival of 16.9 months, compared to 5.5 months for patients with low scores. The analysis further showed that there was no significant interaction between chemotherapy regimen (cisplatin versus carboplatin) and DRP score for any endpoint, supporting the potential applicability of the biomarker across both platinum agents. No significant association was observed between DRP score and response rate. These data build on the Company's previously announced findings and further support the clinical relevance of Platin-DRP in advanced NSCLC. The ELCC presentation is based on a retrospective blinded translational analysis conducted under a prospective-retrospective design using material from the randomized Phase III SPLENDOUR study. The poster concludes that high DRP scores were associated with improved PFS and OS in platinum-treated advanced NSCLC and that, in the absence of validated predictive biomarkers for cis- and carboplatin, the results suggest that Platin-DRP may offer guidance in both clinical trials and practice. Further validation studies are ongoing, including evaluation of the predictive role of the biomarker in platinum plus immunotherapy settings. Cisplatin and its sister molecule carboplatin have been cornerstones in lung cancer therapy for decades. Despite advances in immunotherapy, platinum drugs remain critical in treatment regimens, including combinations with PD-1/L1 inhibitors. While numerous efforts to predict cisplatin efficacy have failed, the Platin-DRP, based on a 205-gene biomarker signature, has shown promising results in other settings, including adjuvant therapy in NSCLC and progression-free survival in breast cancer. As previously announced, CHOSA is also exploring the predictive potential of Platin-DRP in those treated with carboplatin in lung cancer. Data from the SPLENDOUR trial provides a unique opportunity to validate this tool in a large cohort and potentially confirm its utility across both drugs. Future research will also aim to determine whether Platin-DRP can predict the effectiveness of platinum drugs combined with PD-1/L1 inhibitors. Platin-DRP is a validated test designed to help identify patients most likely to benefit from cis- and carboplatin treatment. Strong phase 2b data in metastatic breast cancer have shown that patients selected by DRP responded better to treatment, had longer progression-free survival, and may also have achieved longer overall survival than patients identified as unlikely to respond well. Platin-DRP has also demonstrated its ability to predict the benefit of cisplatin in lung cancer. Cisplatin treatment after surgery remains a gold standard that can improve cure rates, but doctors have not had a validated tool to identify which patients are most likely to benefit. Platin-DRP was validated in a blinded retrospective study in two lung cancer patient cohorts receiving cisplatin after surgery to eliminate residual tumour cells. Patients with the 10% highest scores had a 3-year survival of 90%, whereas patients with the lowest 10% scores had a 3-year survival of only 40%. Cisplatin has often been shown to activate the immune system, potentially making "cold" tumours more susceptible to PD-1 inhibitors. This synergy may be important not only in lung cancer, but also in bladder cancer and head & neck cancer. In the growing PD-1 inhibitor market, CHOSA's approach may offer the ability to predict whether platin can provide synergy with PD-1 inhibition, potentially creating a meaningful advantage for treatment selection and future partners. Announcement • Jan 28
Chosa Oncology AB to Report Fiscal Year 2025 Results on Feb 26, 2026 Chosa Oncology AB announced that they will report fiscal year 2025 results on Feb 26, 2026 Announcement • Jan 23
CHOSA Oncology AB Announces its International Patent Application Has Been Published Under the Patent Cooperation Treaty CHOSA Oncology AB announced that its international patent application has been published under the Patent Cooperation Treaty (PCT), covering CHOSA's predictive technology designed to identify cancer patients likely to benefit from treatment combining platinum-based chemotherapy with PD-(L)1 immunotherapy. The patent application describes a method that uses biological information derived from a patient's tumour to predict treatment response prior to therapy initiation. The technology focuses on combination regimens involving established cisplatin or carboplatin, used together with immune checkpoint inhibitors targeting the PD-1 or PD-L1 pathway. These combination therapies remain cornerstones across multiple cancer indications, however patient response varies considerably. Many patients benefit but there are also too many patients experiencing limited or no benefit while being exposed to significant side effects, high treatment costs, and they may even be deprived of a potentially more effective treatment. The patented method aims to address this challenge by supporting more informed treatment selection, reducing reliance on trial-and-error approaches in the clinical decision-making. Cisplatin and its sister molecule carboplatin have been cornerstones in lung cancer chemotherapy for decades. Despite advances in immunotherapy, platinum drugs remain critical in treatment regimens, including combinations with PD- 1/L1 inhibitors. While numerous efforts to predict cisplatin efficacy have failed, the Cisplatin-DRP, based on a 205-gene biomarker signature, has shown promising results in other settings, including adjuvant therapy in NSCLC and progression-free survival in breast cancer. As previously announced CHOSA is also exploring the predictive potential of the Cisplatin- DRP not only in cisplatin-treated patients but also in those treated with carboplatin in lung cancer. Data from the SPLENDOUR trial provides a unique opportunity to validate this tool in a large cohort, potentially confirming its utility across both drugs. Future research will aim to determine whether the Cisplatin-drP can predict the effectiveness of combinations of platinum drugs with PD-1/L1 inhibitors. CHOSA in short: CHOSA Oncology AB is an oncology biotechnology company led by a proven international team with veteran specialists in oncology; drug development; running clinical trials; regulatory expertise; and business development. CHOSA intends to enter into agreements for partnership or sublicensing of LiPlaCis and the DRP®?. About Cis-DRP, a test to predict if cisplatin treatment is likely to be successful. The cisplatin DRP is the only proven test to foresee and thereby select who to treat and who will benefit from cisplatin. Breast: The cisplatin DRP has previously shown its ability to foresee the value of cisplatin therapy in lung cancer. Cisplatin therapy after surgery is a gold standard that increases lung cancer cure, but not always, and until now the doctors do not know who will benefit from cisplating and who should have something else. This is where the cisplatin DRP is a potential game changer, especially in newneoadjuvant treatment where immunotherapy obtains high efficacy rates when combined with cisplatin doubles. Cisplatin DRP was validated in a blinded retrospective study in two lung cancer patient cohorts receiving cisplatin after surgery to kill remaining tumor cells. Thus, patients with the 10 patients with the 10 patients with a 10-year-year-year-year study. Announcement • Nov 10
CHOSA Oncology AB Announces Platinum Chemotherapy Is the Backline of PD-1/PD-L1-Based Lung Cancer Therapy CHOSA Oncology AB announced - While immune checkpoint inhibitors (PD-1/PD-L1 drugs) have transformed the treatment landscape in advanced non-small cell lung cancer (NSCLC), a new meta-analysis and updated treatment guidelines make it clear that these regimens continue to rely on platinum chemotherapy - specifically cisplatin and carboplatin - as their foundation. In recent years, immunotherapy has often been communicated simply as PD-L1 inhibitor + chemotherapy, creating the perception that chemotherapy could eventually be phased out. However, the 2025 treatment overview presented by Jarushka Naidoo (MD BCH MHS) and a comprehensive Frontiers in Oncology meta-analysis underline that platinum combinations remain indispensable in achieving survival benefit. This insight also extends to the next generation of combination regimens, including bispecific antibodies and dual-checkpoint (PD-1 + CTLA-4) approaches, where platinum-based chemotherapy continues to serve as the immunologic primer for tumor response. The test, based on a 205-gene Platin-DRP signature, has previously been validated for cisplatin in two independent, blinded lung cancer clinical trial datasets and in a prospective phase 2 breast cancer study. In a recent collaboration with ETOP/EORTC the Platin-DRP®? was independently validated and showed prediction of survival for lung cancer patients treated with carboplatin as well as carboplatin. The same predictor was evaluated in a cohort of 20 breast cancer patients treated with carboplating, to assess whether a cisplatin-derived signature could predict response to its sister compound. The results were statistically significant and supportive - forming the basis of CHOSA's Poster presentation at the annual ESMO conference. As previously announced CHOSA is also exploring the predictive potential of the Cisplatin-DRP not only in cisplatin-treated patients but also in those treated with carboplatin in lung cancer. Data from the SPLENDOUR trial provides a unique opportunity to validate this tool in a large cohort, potentially confirming its utility across both drugs. Future research will aim to determine whether the Cisplatin- DRP can predict the effectiveness of combinations of platinum drugs with PD-1/L1 inhibitors. CHOSA in short: CHOSA intends to enter into agreements for partnership or sublicensing of LiPlaCis and the DRP®?. About Cis-DRP, a test to predict if cisplatin treatment is likely to be successful. CHOSA is focused on late-stage clinical development of LiPlaCis®? and its DRP®? drug response predictor to which it has worldwide rights. The cisplatin DRP is the only proven test to foresee and thereby select who to treat and who will benefit from cisplatin. Breast: We have strong phase 2b data in metastatic breast cancer, demonstrating that patients selected by DRP®? responded better to treatment; have longer progression-free survival; and maybe even an overall longer total survival than those patients who were identified as unlikely to respond well to the treatment. Lung: The cisplatin DRP has previously shown its ability to foresee the value of cisplatin therapy in lung cancer. Cis therapy after surgery is a gold standard that increases lung cancer cure, but not always, and until now the doctors do not know who will benefit from cisplating and who should have something else. This is where the cisplatin DRP is a potential game changer, especially in new neoadjuvant treatment where immunotherapytains high efficacy and high efficacy. Announcement • Oct 21
CHOSA Oncology AB Presents Data on the Cisplatin Response Predictor in Breast Cancer Patients on the ESMO Conference CHOSA Oncology AB announced its new clinical data presented at the ESMO 2025 Annual Congress Poster session in Berlin, demonstrating the ability of its cisplatin-derived Drug Response Predictor (Platin-DRP®?) to predict clinical benefit from carboplatin in patients with metastatic breast cancer (MBC). The title of was: "Validation of a cisplatin response predictor in carboplatin-treated metastatic breast cancer patients". This marks the fifth independent clinical validation of the cisplatin DRP®?, further supporting its potential to guide individualized treatment decisions across multiple cancer types and platinum-based regimens. The study analysed gene expression data from 20 metastatic breast cancer patients treated with carboplatin within the Danish Breast Cancer Group (DBCG) cohort. Patients were stratified by their Platin-DRP®? score, a transcriptomic biomarker derived from a 205-gene expression signature that quantifies tumor sensitivity to platinum chemotherapy. If the cancer is resistant to platinum-based drugs, the patient may not gain the same advantage, making it important to find out in advance who is likely to respond. CHOSA has global rights to a patented gene test identifying cancer patients most likely to benefit from treatment with cisplatin and now supported by positive data in carboplatin as well. This tool can help clinicians and patients make more informed decisions about platinum-based chemotherapy: guiding treatment toward those with a high likelihood of response and helping avoid ineffective and potentially toxic therapy for those unlikely to benefit. Announcement • Oct 15
Chosa Oncology AB to Report Q3, 2025 Results on Nov 13, 2025 Chosa Oncology AB announced that they will report Q3, 2025 results on Nov 13, 2025 